ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för rigosertib sodium. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

22 träffar

Bibliografisk träff 2017-12-11

Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.

Dietrich P, Freese K, Mahli A, Thasler WE, Hellerbrand C, Bosserhoff AK.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.23188

Bibliografisk träff 2017-10-01

Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent.

Jost M, Chen Y, Gilbert LA, Horlbeck MA, Krenning L, Menchon G, Rai A, Cho MY, Stern JJ, Prota AE, Kampmann M, Akhmanova A, Steinmetz MO, Tanenbaum ME, Weissman JS.

Mol Cell · research-article; journal article · DOI 10.1016/j.molcel.2017.09.012

Bibliografisk träff 2016-11-01

ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.

Prasad A, Khudaynazar N, Tantravahi RV, Gillum AM, Hoffman BS.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.12692

Bibliografisk träff 2016-04-13

ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex.

Dai YH, Hung LY, Chen RY, Lai CH, Chang KC.

Transl Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.trsl.2016.04.001

Bibliografisk träff 2014-10-14

In vitro antitumor mechanism of (E)-N-(2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)pyridin-3-yl)methanesulfonamide.

Lu T, Laughton CA, Wang S, Bradshaw TD.

Mol Pharmacol · journal article · DOI 10.1124/mol.114.093245

Bibliografisk träff 2014-04-18

Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.Na.

Mäki-Jouppila JH, Laine LJ, Rehnberg J, Narvi E, Tiikkainen P, Hukasova E, Halonen P, Lindqvist A, Kallio L, Poso A, Kallio MJ.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-13-0685

Bibliografisk träff 2014-02-03

Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.

Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Varella-Garcia M, Vogler BW, Keysar SB, Freas E, Aisner DL, Ren C, Tan AC, Wilhelm F, Maniar M, Eckhardt SG, Messersmith WA, Jimeno A.

Clin Cancer Res · research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-13-2506

Bibliografisk träff 2013-06-20

Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer.

Ohnuma T, Lehrer D, Ren C, Cho SY, Maniar M, Silverman L, Sung M, Gretz HF, Benisovich V, Navada S, Akahoho E, Wilck E, Taft DR, Roboz J, Wilhelm F, Holland JF.

Am J Cancer Res · research-article; journal article

Bibliografisk träff 2013-03-25

Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposure.

White MP, Babayeva M, Taft DR, Maniar M.

J Pharm Pharmacol · journal article · DOI 10.1111/jphp.12057

Bibliografisk träff 2013-03-14

Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies.

Roschewski M, Farooqui M, Aue G, Wilhelm F, Wiestner A.

Leukemia · letter; research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; clinical trial, phase i · DOI 10.1038/leu.2013.79

Bibliografisk träff 2013-02-06

Hydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910·Na (Rigosertib®), a phase III clinical stage anti-cancer agent.

Pallela VR, Mallireddigari MR, Cosenza SC, Akula B, Subbaiah DR, Reddy EP, Reddy MV.

Org Biomol Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1039/c3ob27220f

Bibliografisk träff 2012-06-08

Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy.

Nuthalapati S, Zhou Q, Guo P, Lv H, Cosenza S, Reddy MV, Reddy EP, Gallo JM.

Pharm Res · journal article; research support, n.i.h., extramural · DOI 10.1007/s11095-012-0780-y

Bibliografisk träff 2012-04-21

Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.

Olnes MJ, Shenoy A, Weinstein B, Pfannes L, Loeliger K, Tucker Z, Tian X, Kwak M, Wilhelm F, Yong AS, Maric I, Maniar M, Scheinberg P, Groopman J, Young NS, Sloand EM.

Leuk Res · research support, n.i.h., intramural; research-article; clinical trial, phase i; journal article · DOI 10.1016/j.leukres.2012.04.002

Bibliografisk träff 2012-02-20

ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.

Chapman CM, Sun X, Roschewski M, Aue G, Farooqui M, Stennett L, Gibellini F, Arthur D, Pérez-Galán P, Wiestner A.

Clin Cancer Res · research support, n.i.h., intramural; research-article; journal article · DOI 10.1158/1078-0432.ccr-11-2113

Bibliografisk träff 2011-09-14

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.

Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL.

Leuk Res · clinical trial, phase ii; research support, non-u.s. gov't; research-article; clinical trial, phase i; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1016/j.leukres.2011.08.022

Bibliografisk träff 2011-08-17

Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity.

Reddy MV, Venkatapuram P, Mallireddigari MR, Pallela VR, Cosenza SC, Robell KA, Akula B, Hoffman BS, Reddy EP.

J Med Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1021/jm200570p

Bibliografisk träff 2011-06-06

Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation.

Oussenko IA, Holland JF, Reddy EP, Ohnuma T.

Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/0008-5472.can-10-1603

Bibliografisk träff 2009-05-24

Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.

Chun AW, Cosenza SC, Taft DR, Maniar M.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1007/s00280-009-1022-9

Bibliografisk träff 2008-11-24

Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.

Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M.

Oncogene · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/onc.2008.424

Bibliografisk träff 2008-10-27

Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.

Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, Donehower RC.

J Clin Oncol · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1200/jco.2008.17.9788

Bibliografisk träff 2007-06-07

Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma.

Li J, Zhao M, Jimeno A, He P, Ramana Reddy MV, Hidalgo M, Donehower RC, Rudek MA.

J Chromatogr B Analyt Technol Biomed Life Sci · research support, non-u.s. gov't; research-article; validation study; journal article · DOI 10.1016/j.jchromb.2007.05.047

Bibliografisk träff 2005-03-01

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, Jiang J, Holland J, Reddy EP.

Cancer Cell · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ccr.2005.02.009